DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • France
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
DIM logo

Sartorius Stedim Biotech S.A. Stock Price

ENXTPA:DIM Community·€18.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

DIM Share Price Performance

€190.60
15.90 (9.10%)
​
€232.21
Fair Value
€190.60
15.90 (9.10%)
17.9% undervalued intrinsic discount
€232.21
Fair Value
Price €190.60
AnalystConsensusTarget €232.21
Fri, 26 Jun 26
Fair Value€232.21
Share Pricen/a

DIM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €232.21 17.9% undervalued intrinsic discount

High Consumable Demand And Regulatory Standards Will Drive Future Success

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
DIM logo
Sartorius Stedim Biotech
17.9% undervalued intrinsic discount

High Consumable Demand And Regulatory Standards Will Drive Future Success

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
DIM logo

DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk

Fair Value: €232.21 17.9% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Reasonable growth potential with proven track record.

1 Risk
3 Rewards
View Full Analysis

Sartorius Stedim Biotech S.A. Key Details

€3.0b

Revenue

€1.7b

Cost of Revenue

€1.3b

Gross Profit

€1.1b

Other Expenses

€292.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
3.01
44.87%
9.74%
52.5%
View Full Analysis

About DIM

Founded
1978
Employees
10477
CEO
Rene Faber
WebsiteView website
www.sartorius.com

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Recent DIM News & Updates

Analysis Article • Jul 26

Sartorius Stedim Biotech S.A. Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Shareholders might have noticed that Sartorius Stedim Biotech S.A. ( EPA:DIM ) filed its half-yearly result this time...
User avatar
Narrative Update • Jun 26

DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk

The analyst price target for Sartorius Stedim Biotech has been trimmed by €7.93 to €232.21, as analysts factor in slightly higher risk, a modestly lower profit margin outlook, and updated sector views that still identify early signs of recovery in bioprocessing. Analyst Commentary Recent commentary on Sartorius Stedim Biotech reflects a mix of optimism about early recovery signals in bioprocessing and caution about sector risk, which feeds directly into how analysts are thinking about valuation, execution, and growth over the medium term.

Recent updates

No updates

Sartorius Stedim Biotech S.A. Competitors

SAN logo

Sanofi

Symbol: ENXTPA:SAN
Market cap: €88.9b
IPN logo

Ipsen

Symbol: ENXTPA:IPN
Market cap: €13.0b
ERF logo

Eurofins Scientific

Symbol: ENXTPA:ERF
Market cap: €12.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide